Interleukin-8 modulates growth and invasiveness of estrogen receptor-negative breast cancer cells
✍ Scribed by Chen Yao; Ying Lin; Mei-Sze Chua; Cai-Sheng Ye; Jiong Bi; Wen Li; Yi-Fan Zhu; Shen-Ming Wang
- Publisher
- John Wiley and Sons
- Year
- 2007
- Tongue
- French
- Weight
- 439 KB
- Volume
- 121
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Breast cancer, especially estrogen receptor (ER)‐negative breast cancer, remains hard to treat despite major advances in surgery and adjuvant therapies. The deletion of ER has been consistently associated with tumor progression, recurrence, metastasis and poor prognosis. Among other differences in biological features, ER‐negative breast cancers express high levels of interleukin‐8 (IL‐8), whereas their ER‐positive counterparts do not. IL‐8 is a multi‐functional cytokine with many important biological functions in tumor formation and development. We aimed to study the role(s) of IL‐8 in ER‐negative breast cancer progression by using RNA interference to specifically knockdown IL‐8 expression in ER‐negative breast cancer cell lines MDA‐MB‐231 and MDA‐MB‐468. In vitro, suppression of IL‐8 led to significant reductions in cell invasion (p < 0.001), but had no effects on cell proliferation or cell cycle. In vivo, suppression of IL‐8 significantly reduced the microvessel density (p < 0.05), and markedly reduced neutrophil infiltration into the tumors (p < 0.05). In contrast to in vitro observations, suppression of IL‐8 promoted tumor growth in nude mice (p < 0.05). Our results imply that the complex roles of IL‐8 in the regulation of ER‐negative breast cancer progression may in part be related to its potent chemotactic effects on neutrophils, which in turn mediates many of the biological functions of IL‐8. © 2007 Wiley‐Liss, Inc.
📜 SIMILAR VOLUMES
## Abstract The interaction between 17β‐estradiol and estrogen receptor alpha (ER‐α) plays an important role in breast carcinogenesis and breast cancer treatment. ER‐α is a critical growth regulatory gene in breast cancer and its expression level is tightly linked to the prognosis and treatment out
## Abstract Estrogen receptor (ER)‐positive breast cancer cells have low levels of constitutive NF‐κB activity while ER negative (−) cells and hormone‐independent cells have relatively high constitutive levels of NF‐κB activity. In this study, we have examined the aspects of mutual repression betwe
## Abstract We show that siRNA‐mediated suppression of protein tyrosine phosphatase α (PTPα) reduces Src activity 2 to 4‐fold in breast, colon and other human cancer cell lines. Src and PTPα RNAi induced apoptosis in estrogen receptor (ER)‐negative breast cancer and colon cancer cells, but not in i
## Abstract ## BACKGROUND Breast cancers that are negative for estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) (triple negative [TN]) have been associated with high‐grade histology, aggressive clinical behavior, and poor survival. It has been